DUBLIN–(BUSINESS WIRE)–The «In Vitro Diagnostic Collaboration and Licensing Deals 2016-2025» has been added to ResearchAndMarkets.com’s offering.
This report contains a comprehensive listing of 289 in vitro diagnostic deals announced since 2016, including financial terms where available, with links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the in vitro diagnostic deals entered into by the world’s leading biopharma companies.
Fully revised and updated, the report provides details of in vitro diagnostic deals from 2016 to 2025. The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking. Chapter 1 provides an introduction to the report, while Chapter 2 offers an overview of the trends in in vitro diagnostic dealmaking since 2016. Chapter 3 highlights the leading in vitro diagnostic deals since 2016, sorted by headline value. Chapter 4 gives a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking, along with a detailed list of deals and available public contract documents. Chapter 5 and Chapter 6 offer a detailed review of deals signed and announced since January 2016, with Chapter 6 focusing specifically on various in vitro diagnostic technology types. The report also includes numerous tables and figures that illustrate trends and activities in in vitro diagnostic dealmaking since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.
In Vitro Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse in vitro diagnostic collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms – upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents – insights into deal structures
- Due diligence – assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
In Vitro Diagnostic Collaboration and Licensing Deals includes:
- Trends in in vitro diagnostic dealmaking in the biopharma industry
- Directory of in vitro diagnostic deal records covering pharmaceutical and biotechnology
- The leading in vitro diagnostic deals by value
- Most active in vitro diagnostic licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in in vitro diagnostic dealmaking
2.1. Introduction
2.2. In vitro diagnostic deals over the years
2.3. Most active in vitro diagnostic dealmakers
2.4. In vitro diagnostic deals by deal type
2.5. In vitro diagnostic deals by therapy area
2.6. In vitro diagnostic deals by industry sector
2.7. Deal terms for in vitro diagnostic deals
2.7.1 In vitro diagnostic deals headline values
2.7.2 In vitro diagnostic deal upfront payments
2.7.3 In vitro diagnostic deal milestone payments
2.7.4 In vitro diagnostic royalty rates
Chapter 3 – Leading in vitro diagnostic deals
3.1. Introduction
3.2. Top in vitro diagnostic deals by value
Chapter 4 – Most active in vitro diagnostic dealmakers
4.1. Introduction
4.2. Most active in vitro diagnostic dealmakers
4.3. Most active in vitro diagnostic deals company profiles
Chapter 5 – In vitro diagnostic contracts dealmaking directory
5.1. Introduction
5.2. In vitro diagnostic contracts dealmaking directory
Chapter 6 – In vitro diagnostic dealmaking by technology type
Deal directory
Deal directory – In vitro diagnostic deals by company A-Z
Deal directory – In vitro diagnostic deals by deal type
Deal directory – In vitro diagnostic deals by therapy area
Deal type definitions
Companies Featured
- 2cureX
- 3M
- 23andMe
- Abbott Laboratories
- Actelion
- Agilent Technologies
- Alexion Pharmaceuticals
- AliveCor
- Allogene Therapeutics
- American Type Culture Collection (ATCC)
- Anixa Biosciences
- AstraZeneca
- Avacta
- Bayer
- Beckman Coulter
- Bio-Rad Laboratories
- bioMerieux
- Biotage
- Brigham and Women’s Hospital
- Cardiff University
- Cepheid
- Cleveland Clinic
- Columbia University
- Danaher
- Dako
- Eli Lilly
- Epizyme
- Fujirebio Diagnostics
- Genentech
- Georgetown University
- Ginkgo BioWorks
- Guardant Health
- Hologic
- Illumina
- Inova Diagnostics
- Invitae
- Janssen Pharmaceuticals
- Johns Hopkins University
- Lexent Bio
- Massachusetts Institute of Technology
- Mayo Clinic
- Medigus
- Memorial Sloan Kettering Cancer Center
- Monsanto
- Novartis
- OraSure Technologies
- Oxford Nanopore Technologies
- PerkinElmer
- Pfizer
- Qiagen
For more information about this report visit https://www.researchandmarkets.com/r/gu3hdy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
